2

TO THE EDITOR:
The key event in the pathogenesis of Systemic light chain amyloidosis (AL) is an unstable misfolded secondary or tertiary structure of a monoclonal immunoglobulin (IG) light chain, that precipitates in the extracellular compartments. 1 The plasma-cell disorder underlying AL, is likely to lie within the common spectrum of plasma-cell diseases, but limited confirmatory data analysing the genetic architecture of AL are available. 2 To address this, we prospectively included twenty-four newly diagnosed histologically proven AL samples from the National Amyloid Centre, University College London, UK, prior to any treatment. AL was confirmed by immunohistochemistry or mass spectrometry.
CD138+ cells and peripheral blood were isolated, DNA extracted and used in an exome capture protocol and sequenced as previously published. 3 This AL dataset was compared to previously published MGUS 4 and MM 5, 6 datasets and filtered similarly to ensure comparability of mutation numbers. Detailed methods and Patient's characteristics may be found in the Supplemental-Methods and Supplemental- Table 1 .
In terms of mutational burden, the median number of exonic, non-IG, non-synonymous mutations per sample that had a tumour variant allelic fraction greater than 5% was 39 (interquartile range (IQR): 5-185) which is more than was seen in MGUS 4 (20 (IQR: 1-41), p=0.002) but not statistically different from MM 6 (35 (IQR: 3-74), p=0.4), Figure 1A . When analysing the individual genes, we identified a total of 1491 genes that were mutated in our dataset with 236 of them being mutated more than once. As expected, there was no unifying mutation in AL. The dataset was too small to identify any significantly mutated genes. 7 Among the recurrently mutated genes (Supplemental- Table 2) , mutations in IL7R, a gene that encodes for a cell surface receptor known to regulate V(D)J recombination by altering the accessibility of DNA substrates to the recombinase in pro-B-cells, 8 were noted. Thirtyseven percent of samples (n=9) had a mutation in one of the 63 previously described MMdriver genes. 9 This is less than MM (84.1%) 9 and similar to MGUS (36%). 4 The number of mutated driver-genes per sample ranged from zero to five. Among the 63 driver-genes, 13
were mutated, Table 1 . Most of these mutations were sub-clonal with IG-adjusted estimated tumour fractions ranging from 18% to 100% (Supplemental- Table 3 ). We identified cases with MM hotspot mutations in NRAS (Q61R and Q61H) but not in KRAS. Even though a trend for fewer KRAS mutations in AL was observed, there was no significant difference in the incidence of driver mutations between MM, MGUS, and AL, Figure 1B . Interestingly there were mutations in some of the other driver-genes such as EGR1 (Q95R), DIS3 (D479E,
For personal use only. on December 4, 2018. by guest www.bloodjournal.org From M667L), IRF4 (S332G), and TRAF3 (K99_sp). Only the same TRAF3 (K99_sp) and DIS3 (D479E, M667L) mutations were seen in the MM dataset, Supplemental- Figure 1A -E. 9 In MM, IRF4 mutations are associated with t (11;14) , and in this AL dataset the IRF4 mutation (S332G) occurred in a non t(11;14) patient and was neither at the K123R hotspot seen in MM 6 nor the L116R seen in CLL. 10 There were no mutations in the previously reported adverse prognostic genes such as ATM, ATR, ZFHX4 and TP53, nevertheless mutations in BRCA2 (P1088T, N372H) and the driver-gene EP300 (I997V) were seen suggesting DNArepair pathway involvement. Copy-number analysis did not reveal any copy number changes at these loci suggesting the absence of bi-allelic inactivation. They were all generated via class switch recombination with breakpoints occurring in the IGHA1 (2/7) and IGHM (5/7) switch regions. There was no evidence of other canonical translocation but we identified a t(1;14) involving IGHG4 and the RCC1 gene in a t (11;14) patient, Supplemental- Figure 5 . There was no evidence of inter-chromosomal translocations involving MYC; one patient had an 8q24 gain, 5' to MIR1208, suggesting MYC rearrangements also occur in AL. Regarding other cytogenetic abnormalities, there was no difference in the incidence of copy number changes with the exception of del(1p), and This is the largest dataset of whole exome sequencing (WES) of AL to date and combined, these data suggest the underlying disease in AL resembles other plasma-cell disorders such as MGUS and MM. The number of mutations in AL was comparable to MM suggesting AL is a more complex disease than MGUS. Like previously published AL cases that had undergone WES, 2 we failed to identify any unifying mutation. We were nonetheless able to detect MMdefined driver mutations. They occurred at similar frequencies to MGUS and were less common than in MM. They were predominantly sub-clonal suggesting they occurred late during disease progression. There was evidence of mitogen activated protein kinase (MAPK) activation with NRAS mutations (8%) in keeping with previously published data by Rossi et al 16 , NF-κB activation (17%) and DNA-repair pathway alterations (12%).Unlike previous reports, none of the NRAS mutated patients had classical CRAB criteria but one had another myeloma defining event (SFLC ratio>100 with an involved chain greater than 1000 mg/L).
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These data are consistent with observations from MGUS and SMM where NRAS mutations may be found with lower frequencies than in MM. 4, 16, 18 There was a 93% overlap in mutated genes indicating a common spectrum of mutations between AL and other plasma-cell disorders. Attempts to cluster patients based on MM-driver genes placed AL close to MM and MGUS and not with other lymphoid malignancies.
Overall AL showed a similar mutation burden to MM but resembled MGUS in terms of copy number changes and driver-gene mutations suggesting AL lies within the continuous spectrum from MGUS to MM. Given that the similarities with MGUS and MM are outweighing the differences, it is unlikely that the plasmacell biology per se explains the clinical presentation of AL, however, these data support the ongoing use of myeloma-based therapy for this disease. KRAS  NRAS  DIS3  FAM46C  BRAF  TP53  HUWE1  TRAF3  EGR1  DUSP2  IRF4  ZNF292  KLHL6  KMT2C  CREBBP  ATRX  KMT2B  EP300  TET2  SAMHD1  RASA2  ZFP36L1 A.
B.
ATM SF3B1  TP53  HIST1H1E  KLHL6  ZFP36L1  CREBBP  KRAS  FAM46C  BRAF  DIS3  NRAS  EGR1  EP300  DUSP2  HUWE1  ACTG1  LTB  NFKBIA  RFTN1  ATRX  SETD2  CCND1  CDKN1B  PRKD2  SAMHD1  KMT2B  TET2  TRAF3  ZNF292  IRF4  C8ORF34  PIK3CA  ARID2  DNMT3A  ABCF1  NFKB2  RASA2  TGDS  IDH2  MAFB  CDKN2C  MAF  MAN2C1  IDH1  MAML2  NCOR1  XBP1  FGFR3  UBR5  CYLD  MAX  KDM6A  KDM5C  PRDM1  RB1  SP140  NF1  FUBP1  KMT2C  TRAF2 
